Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Abbisko Cayman Limited (2256.HK)
Shanghai, CN
Founded in 2016 and headquartered in Shanghai, People's Republic of China, Abbisko Cayman Limited operates as a clinical-stage biopharmaceutical company. Its core mission involves the discovery and advancement of small molecule oncology therapeutics. The company's development efforts primarily target small molecule precision oncology and immuno-oncology therapeutic areas. Among its prominent product candidates are ABSK011, a small molecule designed to inhibit fibroblast growth factor receptor 4, intended for advanced hepatocellular carcinoma characterized by hyper-activation of FGF19/FGFR4 signaling. Another significant asset is ABSK091, a molecularly targeted candidate addressing a range of solid tumors, including urothelial, gastric, cholangiocarcinoma, and lung cancers. Furthermore, Abbisko Cayman Limited maintains a broader pipeline of other promising product candidates.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.77% | -4.32% | -24.54% | -23.29% | -31.82% | -25.06% | +1.77% | +248.21% | -21.37% | -21.37% | -21.37% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | -2 |
| Buy | 10 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+18.3% ★ Q2'25: +23.1% (vs Q2'24)
-
EPS growth Biotechnology: +29.7%+110.5% ★ Q2'25: +56.3% (vs Q2'24)
-
FCF margin FCF growth · Biotechnology: +16.2%-5.0% Q2'25: +49.2% (vs Q2'24)
-
EBIT margin Biotechnology: +0.0%+4.6% ★ Q2'25: +57.0% (vs Q2'24)
-
ROIC Biotechnology: -16.1%+12.9% ★ Q2'25: +463.3% (vs Q2'24)
-
Share dilution Biotechnology: -3.4%-1.5% ★ Q2'25: -2.0% (vs Q2'24)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×6.21× ★ Q2'25: 0.43× (vs Q2'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 4 EPS Ana. |
Dec 2027 8 Rev. Ana. 6 EPS Ana. |
Dec 2028 5 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
22.68M
est: 5.51M (+311.8%)
|
—
est: 19.06M (-100.0%)
|
19.06M
est: 462.56M (-95.9%)
|
503.99M
est: 521.21M (-3.3%)
|
596.28M
est: 640.69M (-6.9%)
|
410.59M
108.93M – 708.22M
-35.9% YoY
|
567.96M
434.15M – 780.87M
+38.3% YoY
|
690.17M
386.97M – 1.05B
+21.5% YoY
|
| EBITDA |
-1.80B
est: -33.4K (-5,381,388.2%)
|
-492.62M
est: -115.6K (-426,204.1%)
|
-410.99M
est: -87.73M (-368.5%)
|
-15.28M
est: -98.85M (+84.5%)
|
48.93M
est: -121.51M (+140.3%)
|
-77.87M
-134.32M – -20.66M
+35.9% YoY
|
-107.72M
-148.09M – -82.34M
-38.3% YoY
|
-130.89M
-198.66M – -73.39M
-21.5% YoY
|
| EBIT |
-1.81B
est: -47.2K (-3,832,518.0%)
|
-497.19M
est: -163.3K (-304,311.4%)
|
-429.41M
est: -92.26M (-365.4%)
|
-21.59M
est: -103.96M (+79.2%)
|
27.18M
est: -127.79M (+121.3%)
|
-81.89M
-141.26M – -21.73M
+35.9% YoY
|
-113.28M
-155.75M – -86.59M
-38.3% YoY
|
-137.66M
-208.92M – -77.18M
-21.5% YoY
|
| Net Income |
-1.81B
est: -1.18B (-52.9%)
|
-498.29M
est: -482.59M (-3.3%)
|
-431.58M
est: -15.07M (-2,764.0%)
|
28.30M
est: -50.41M (+156.1%)
|
53.82M
est: 49.62M (+8.5%)
|
-58.60M
-613.76M – 129.21M
-218.1% YoY
|
-94.48M
-553.80M – 112.91M
-61.2% YoY
|
-146.02M
-244.29M – -62.63M
-54.5% YoY
|
| SGA |
54.84M
est: 7.09M (+673.7%)
|
29.82M
est: 24.52M (+21.6%)
|
35.61M
est: 514.10M (-93.1%)
|
74.21M
est: 579.28M (-87.2%)
|
73.81M
est: 712.07M (-89.6%)
|
456.33M
121.06M – 787.12M
-35.9% YoY
|
631.24M
482.52M – 867.87M
+38.3% YoY
|
767.06M
430.09M – 1.16B
+21.5% YoY
|
| EPS |
-7.68
est: -1.82 (-322.5%)
|
-0.80
est: -0.74 (-7.9%)
|
-0.67
est: -0.02 (-2,759.5%)
|
0.04
est: -0.07 (+153.4%)
|
0.09
est: 0.13 (-31.4%)
|
-0.34
-0.96 – 0.20
-372.3% YoY
|
-0.16
-0.87 – 0.18
+52.3% YoY
|
-0.23
-0.38 – -0.10
-40.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-29 | B | 3/5 | 1/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-28 | B | 3/5 | 1/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-21 | B | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-20 | B | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-17 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI China Small-Cap ETF ECNS | 0.44% | 287.9K | 0.59% |
| 2 | WisdomTree China ex-State-Owned Enterprises Fund CXSE | 0.08% | 413.4K | 0.32% |
| 3 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.06% | 77.3K | 0.42% |
| 4 | iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L | 0.06% | 42.0K | 0.74% |
| 5 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.05% | 323.1K | 0.55% |
| 6 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.05% | 333.1K | 0.65% |
| 7 | iShares MSCI EM Small Cap UCITS ETF IEMS.L | 0.04% | 144.1K | 0.74% |
| 8 | iShares MSCI Emerging Markets Small-Cap ETF EEMS | 0.04% | 149.5K | 0.72% |
| 9 | State Street SPDR S&P China ETF GXC | 0.02% | 74.5K | 0.59% |
| 10 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.01% | 2.04M | 0.06% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jing Ji | Chief Medical Officer & Executive Director | 6M | — |
| Yao-Chang Xu | Founder, Chairman of the Board & Chief Executive Officer | 5M | — |
| Hongping Yu | Co-Founder, SVP of Chemistry, Chief Scientific Officer & Executive Director | 3M | — |
| Yin Wah Chan FCCA FCIS HKICS | Joint Company Secretary | — | female |
| Yongyi Li | General Counsel | — | male |
| Zhen Zhang | Senior VP of CMC & Head of Chemistry, Manufacturing and Controls | — | — |
| Hanxi Zhang | Joint Company Secretary | — | female |
| Zidong Zhang | Group Chief Financial Officer | — | — |
| Jia Feng | Vice President of HR and Operations & Head of Human Resource | — | female |
| Sio Ngo Lin | Joint Company Secretary | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2256.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
